Which has higher valuation and earnings, DVA or ALGN?

DaVita has higher revenue and earnings than Align Technology. DaVita is trading at a lower price-to-earnings ratio than Align Technology, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio DaVita $13.64B 0.82 $746.80M $12.22 14.34 Align Technology $4.03B 2.58 $410.35M $5.75 25.28

Is DVA or ALGN more profitable?

Align Technology has a net margin of 9.99% compared to DaVita's net margin of 6.05%. Align Technology's return on equity of 15.86% beat DaVita's return on equity. Company Net Margins Return on Equity Return on Assets DaVita 6.05% -217.63% 5.07% Align Technology 9.99% 15.86% 10.32%

Does the media refer more to DVA or ALGN?

In the previous week, Align Technology had 1 more articles in the media than DaVita. MarketBeat recorded 5 mentions for Align Technology and 4 mentions for DaVita. Align Technology's average media sentiment score of 1.09 beat DaVita's score of 0.00 indicating that Align Technology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment DaVita 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Align Technology 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation and earnings, DVA or DXCM?

DexCom has lower revenue, but higher earnings than DaVita. DaVita is trading at a lower price-to-earnings ratio than DexCom, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio DaVita $13.64B 0.82 $746.80M $12.22 14.34 DexCom $4.66B 6.98 $836.30M $2.53 34.11

Is DVA or DXCM more profitable?

DexCom has a net margin of 20.12% compared to DaVita's net margin of 6.05%. DexCom's return on equity of 35.94% beat DaVita's return on equity. Company Net Margins Return on Equity Return on Assets DaVita 6.05% -217.63% 5.07% DexCom 20.12% 35.94% 14.75%

Does the media favor DVA or DXCM?

In the previous week, DexCom had 6 more articles in the media than DaVita. MarketBeat recorded 10 mentions for DexCom and 4 mentions for DaVita. DexCom's average media sentiment score of 0.58 beat DaVita's score of 0.00 indicating that DexCom is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment DaVita 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral DexCom 3 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings and valuation, HQY or DVA?

DaVita has higher revenue and earnings than HealthEquity. DaVita is trading at a lower price-to-earnings ratio than HealthEquity, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio HealthEquity $1.31B 5.57 $215.20M $2.77 31.95 DaVita $13.64B 0.82 $746.80M $12.22 14.34

Is HQY or DVA more profitable?

HealthEquity has a net margin of 17.36% compared to DaVita's net margin of 6.05%. HealthEquity's return on equity of 15.33% beat DaVita's return on equity. Company Net Margins Return on Equity Return on Assets HealthEquity 17.36% 15.33% 9.51% DaVita 6.05% -217.63% 5.07%

Does the media prefer HQY or DVA?

In the previous week, HealthEquity had 1 more articles in the media than DaVita. MarketBeat recorded 5 mentions for HealthEquity and 4 mentions for DaVita. HealthEquity's average media sentiment score of 1.41 beat DaVita's score of 0.00 indicating that HealthEquity is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment HealthEquity 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive DaVita 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable earnings and valuation, DVA or MMSI?

DaVita has higher revenue and earnings than Merit Medical Systems. DaVita is trading at a lower price-to-earnings ratio than Merit Medical Systems, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio DaVita $13.64B 0.82 $746.80M $12.22 14.34 Merit Medical Systems $1.52B 3.40 $128.49M $2.42 35.63

Does the media refer more to DVA or MMSI?

In the previous week, Merit Medical Systems had 3 more articles in the media than DaVita. MarketBeat recorded 7 mentions for Merit Medical Systems and 4 mentions for DaVita. Merit Medical Systems' average media sentiment score of 1.18 beat DaVita's score of 0.00 indicating that Merit Medical Systems is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment DaVita 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Merit Medical Systems 2 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation and earnings, DVA or CAH?

Cardinal Health has higher revenue and earnings than DaVita. DaVita is trading at a lower price-to-earnings ratio than Cardinal Health, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio DaVita $13.64B 0.82 $746.80M $12.22 14.34 Cardinal Health $254.25B 0.20 $1.71B $7.23 30.86

Is DVA or CAH more profitable?

DaVita has a net margin of 6.05% compared to Cardinal Health's net margin of 0.67%. Cardinal Health's return on equity of -98.53% beat DaVita's return on equity. Company Net Margins Return on Equity Return on Assets DaVita 6.05% -217.63% 5.07% Cardinal Health 0.67% -98.53% 4.69%

Does the media favor DVA or CAH?

In the previous week, Cardinal Health had 4 more articles in the media than DaVita. MarketBeat recorded 8 mentions for Cardinal Health and 4 mentions for DaVita. Cardinal Health's average media sentiment score of 0.51 beat DaVita's score of 0.00 indicating that Cardinal Health is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment DaVita 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cardinal Health 1 Very Positive mention(s) 0 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

DaVita (DVA) Competitors

$175.19 +0.00 (+0.00%)

Closing price 03:59 PM Eastern

Extended Trading

$175.40 +0.20 (+0.12%)

As of 07:30 PM Eastern

Compare

DVA vs. ALGN, DXCM, HQY, MMSI, and CAH

Should you buy DaVita stock or one of its competitors? DaVita's main competitors and comparable companies include Align Technology (ALGN), DexCom (DXCM), HealthEquity (HQY), Merit Medical Systems (MMSI), and Cardinal Health (CAH). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare" sector.

How does DaVita compare to Align Technology?

DaVita (NYSE:DVA) and Align Technology (NASDAQ:ALGN) are both large-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, valuation, institutional ownership, earnings, profitability and risk.

DaVita currently has a consensus target price of $233.43, indicating a potential upside of 33.24%. Align Technology has a consensus target price of $206.36, indicating a potential upside of 41.97%. Given Align Technology's stronger consensus rating and higher possible upside, analysts plainly believe Align Technology is more favorable than DaVita.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DaVita	0 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.43
Align Technology	0 Sell rating(s)	6 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.67

DaVita has higher revenue and earnings than Align Technology. DaVita is trading at a lower price-to-earnings ratio than Align Technology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DaVita	$13.64B	0.82	$746.80M	$12.22	14.34
Align Technology	$4.03B	2.58	$410.35M	$5.75	25.28

In the previous week, Align Technology had 1 more articles in the media than DaVita. MarketBeat recorded 5 mentions for Align Technology and 4 mentions for DaVita. Align Technology's average media sentiment score of 1.09 beat DaVita's score of 0.00 indicating that Align Technology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DaVita	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Align Technology	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

90.1% of DaVita shares are held by institutional investors. Comparatively, 88.4% of Align Technology shares are held by institutional investors. 1.9% of DaVita shares are held by insiders. Comparatively, 0.8% of Align Technology shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

DaVita has a beta of 0.83, suggesting that its share price is 17% less volatile than the broader market. Comparatively, Align Technology has a beta of 1.65, suggesting that its share price is 65% more volatile than the broader market.

Align Technology has a net margin of 9.99% compared to DaVita's net margin of 6.05%. Align Technology's return on equity of 15.86% beat DaVita's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DaVita	6.05%	-217.63%	5.07%
Align Technology	9.99%	15.86%	10.32%

Summary

Align Technology beats DaVita on 12 of the 17 factors compared between the two stocks.

How does DaVita compare to DexCom?

DaVita (NYSE:DVA) and DexCom (NASDAQ:DXCM) are both large-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, earnings, risk, analyst recommendations, institutional ownership, media sentiment and dividends.

90.1% of DaVita shares are held by institutional investors. Comparatively, 97.8% of DexCom shares are held by institutional investors. 1.9% of DaVita shares are held by insiders. Comparatively, 0.3% of DexCom shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, DexCom had 6 more articles in the media than DaVita. MarketBeat recorded 10 mentions for DexCom and 4 mentions for DaVita. DexCom's average media sentiment score of 0.58 beat DaVita's score of 0.00 indicating that DexCom is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DaVita	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
DexCom	3 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

DaVita has a beta of 0.83, suggesting that its stock price is 17% less volatile than the broader market. Comparatively, DexCom has a beta of 1.42, suggesting that its stock price is 42% more volatile than the broader market.

DexCom has lower revenue, but higher earnings than DaVita. DaVita is trading at a lower price-to-earnings ratio than DexCom, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DaVita	$13.64B	0.82	$746.80M	$12.22	14.34
DexCom	$4.66B	6.98	$836.30M	$2.53	34.11

DexCom has a net margin of 20.12% compared to DaVita's net margin of 6.05%. DexCom's return on equity of 35.94% beat DaVita's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DaVita	6.05%	-217.63%	5.07%
DexCom	20.12%	35.94%	14.75%

DaVita currently has a consensus price target of $233.43, indicating a potential upside of 33.24%. DexCom has a consensus price target of $89.08, indicating a potential upside of 3.24%. Given DaVita's higher probable upside, equities research analysts plainly believe DaVita is more favorable than DexCom.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DaVita	0 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.43
DexCom	1 Sell rating(s)	2 Hold rating(s)	20 Buy rating(s)	2 Strong Buy rating(s)	2.92

Summary

DexCom beats DaVita on 13 of the 17 factors compared between the two stocks.

How does DaVita compare to HealthEquity?

HealthEquity (NASDAQ:HQY) and DaVita (NYSE:DVA) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, dividends, institutional ownership, profitability, earnings, media sentiment, analyst recommendations and risk.

HealthEquity currently has a consensus price target of $112.20, suggesting a potential upside of 26.77%. DaVita has a consensus price target of $233.43, suggesting a potential upside of 33.24%. Given DaVita's higher probable upside, analysts clearly believe DaVita is more favorable than HealthEquity.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HealthEquity	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.92
DaVita	0 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.43

HealthEquity has a beta of 0.22, indicating that its stock price is 78% less volatile than the broader market. Comparatively, DaVita has a beta of 0.83, indicating that its stock price is 17% less volatile than the broader market.

In the previous week, HealthEquity had 1 more articles in the media than DaVita. MarketBeat recorded 5 mentions for HealthEquity and 4 mentions for DaVita. HealthEquity's average media sentiment score of 1.41 beat DaVita's score of 0.00 indicating that HealthEquity is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
HealthEquity	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
DaVita	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

DaVita has higher revenue and earnings than HealthEquity. DaVita is trading at a lower price-to-earnings ratio than HealthEquity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HealthEquity	$1.31B	5.57	$215.20M	$2.77	31.95
DaVita	$13.64B	0.82	$746.80M	$12.22	14.34

99.6% of HealthEquity shares are owned by institutional investors. Comparatively, 90.1% of DaVita shares are owned by institutional investors. 1.6% of HealthEquity shares are owned by company insiders. Comparatively, 1.9% of DaVita shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

HealthEquity has a net margin of 17.36% compared to DaVita's net margin of 6.05%. HealthEquity's return on equity of 15.33% beat DaVita's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HealthEquity	17.36%	15.33%	9.51%
DaVita	6.05%	-217.63%	5.07%

Summary

HealthEquity beats DaVita on 11 of the 17 factors compared between the two stocks.

How does DaVita compare to Merit Medical Systems?

DaVita (NYSE:DVA) and Merit Medical Systems (NASDAQ:MMSI) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, risk, media sentiment, earnings, dividends, analyst recommendations, institutional ownership and valuation.

DaVita currently has a consensus target price of $233.43, indicating a potential upside of 33.24%. Merit Medical Systems has a consensus target price of $100.00, indicating a potential upside of 15.97%. Given DaVita's higher probable upside, analysts clearly believe DaVita is more favorable than Merit Medical Systems.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DaVita	0 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.43
Merit Medical Systems	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.83

90.1% of DaVita shares are held by institutional investors. Comparatively, 99.7% of Merit Medical Systems shares are held by institutional investors. 1.9% of DaVita shares are held by insiders. Comparatively, 0.7% of Merit Medical Systems shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

DaVita has a beta of 0.83, meaning that its share price is 17% less volatile than the broader market. Comparatively, Merit Medical Systems has a beta of 0.49, meaning that its share price is 51% less volatile than the broader market.

In the previous week, Merit Medical Systems had 3 more articles in the media than DaVita. MarketBeat recorded 7 mentions for Merit Medical Systems and 4 mentions for DaVita. Merit Medical Systems' average media sentiment score of 1.18 beat DaVita's score of 0.00 indicating that Merit Medical Systems is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DaVita	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Merit Medical Systems	2 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

DaVita has higher revenue and earnings than Merit Medical Systems. DaVita is trading at a lower price-to-earnings ratio than Merit Medical Systems, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DaVita	$13.64B	0.82	$746.80M	$12.22	14.34
Merit Medical Systems	$1.52B	3.40	$128.49M	$2.42	35.63

Merit Medical Systems has a net margin of 9.22% compared to DaVita's net margin of 6.05%. Merit Medical Systems' return on equity of 13.75% beat DaVita's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DaVita	6.05%	-217.63%	5.07%
Merit Medical Systems	9.22%	13.75%	8.10%

Summary

Merit Medical Systems beats DaVita on 11 of the 17 factors compared between the two stocks.

How does DaVita compare to Cardinal Health?

DaVita (NYSE:DVA) and Cardinal Health (NYSE:CAH) are both large-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, dividends, earnings, profitability, valuation and institutional ownership.

In the previous week, Cardinal Health had 4 more articles in the media than DaVita. MarketBeat recorded 8 mentions for Cardinal Health and 4 mentions for DaVita. Cardinal Health's average media sentiment score of 0.51 beat DaVita's score of 0.00 indicating that Cardinal Health is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DaVita	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cardinal Health	1 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cardinal Health has higher revenue and earnings than DaVita. DaVita is trading at a lower price-to-earnings ratio than Cardinal Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DaVita	$13.64B	0.82	$746.80M	$12.22	14.34
Cardinal Health	$254.25B	0.20	$1.71B	$7.23	30.86

90.1% of DaVita shares are owned by institutional investors. Comparatively, 87.2% of Cardinal Health shares are owned by institutional investors. 1.9% of DaVita shares are owned by company insiders. Comparatively, 0.1% of Cardinal Health shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

DaVita currently has a consensus target price of $233.43, indicating a potential upside of 33.24%. Cardinal Health has a consensus target price of $266.56, indicating a potential upside of 19.47%. Given DaVita's higher possible upside, equities research analysts clearly believe DaVita is more favorable than Cardinal Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DaVita	0 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.43
Cardinal Health	0 Sell rating(s)	3 Hold rating(s)	16 Buy rating(s)	0 Strong Buy rating(s)	2.84

DaVita has a beta of 0.83, suggesting that its share price is 17% less volatile than the broader market. Comparatively, Cardinal Health has a beta of 0.51, suggesting that its share price is 49% less volatile than the broader market.

DaVita has a net margin of 6.05% compared to Cardinal Health's net margin of 0.67%. Cardinal Health's return on equity of -98.53% beat DaVita's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DaVita	6.05%	-217.63%	5.07%
Cardinal Health	0.67%	-98.53%	4.69%

Summary

DaVita and Cardinal Health tied by winning 8 of the 16 factors compared between the two stocks.

Get DaVita News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DVA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DVA vs. The Competition

Export

Metric	DaVita	Healthcare Providers & Services Industry	Healthcare Sector	NYSE Exchange
Market Cap	$11.18B	$9.69B	$7.30B	$22.84B
Dividend Yield	N/A	2.59%	2.52%	3.72%
P/E Ratio	14.34	34.19	273.68	27.52
Price / Sales	0.82	4.92	613.83	21.42
Price / Cash	8.07	120.85	79.75	40.95
Price / Book	-33.12	5.16	10.34	4.60
Net Income	$746.80M	$315.68M	$3.50B	$1.08B
7 Day Performance	-4.31%	-2.16%	-1.70%	-1.99%
1 Month Performance	-3.06%	-2.10%	-4.61%	-6.24%
1 Year Performance	31.87%	9.44%	12.41%	5.07%

DaVita Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DVA DaVita	4.5144 of 5 stars	$175.19 +0.0%	$233.43 +33.2%	+33.9%	$11.18B	$13.64B	14.34	78,000
ALGN Align Technology	3.9296 of 5 stars	$146.88 -0.5%	$206.36 +40.5%	+14.0%	$10.57B	$4.03B	25.54	20,290	Positive News
DXCM DexCom	3.4542 of 5 stars	$89.17 -0.2%	$89.08 -0.1%	+30.4%	$33.72B	$4.66B	35.25	11,000	Insider Trade
HQY HealthEquity	4.4736 of 5 stars	$94.52 -0.7%	$112.20 +18.7%	-8.5%	$7.87B	$1.31B	34.12	2,814	Positive News
MMSI Merit Medical Systems	3.4526 of 5 stars	$85.49 +0.1%	$100.00 +17.0%	+8.7%	$5.10B	$1.52B	35.33	7,500	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:DVA) was last updated on 9/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

DaVita (DVA) Competitors

DVA vs. ALGN, DXCM, HQY, MMSI, and CAH

How does DaVita compare to Align Technology?

Summary

How does DaVita compare to DexCom?

Summary

How does DaVita compare to HealthEquity?

Summary

How does DaVita compare to Merit Medical Systems?

Summary

How does DaVita compare to Cardinal Health?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DVA vs. The Competition

DaVita Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

DaVita (DVA) Competitors

DVA vs. ALGN, DXCM, HQY, MMSI, and CAH

How does DaVita compare to Align Technology?

Do analysts prefer DVA or ALGN?

Which has higher valuation and earnings, DVA or ALGN?

Does the media refer more to DVA or ALGN?

Do insiders and institutionals hold more shares of DVA or ALGN?

Which has more risk & volatility, DVA or ALGN?

Is DVA or ALGN more profitable?

Summary

How does DaVita compare to DexCom?

Do insiders and institutionals believe in DVA or DXCM?

Does the media favor DVA or DXCM?

Which has more volatility & risk, DVA or DXCM?

Which has stronger valuation and earnings, DVA or DXCM?

Is DVA or DXCM more profitable?

Do analysts prefer DVA or DXCM?

Summary

How does DaVita compare to HealthEquity?

Do analysts prefer HQY or DVA?

Which has more risk & volatility, HQY or DVA?

Does the media prefer HQY or DVA?

Which has stronger earnings and valuation, HQY or DVA?

Do insiders & institutionals have more ownership in HQY or DVA?

Is HQY or DVA more profitable?

Summary

How does DaVita compare to Merit Medical Systems?

Do analysts prefer DVA or MMSI?

Do insiders and institutionals believe in DVA or MMSI?

Which has more volatility & risk, DVA or MMSI?

Does the media refer more to DVA or MMSI?

Which has preferable earnings and valuation, DVA or MMSI?

Is DVA or MMSI more profitable?

Summary

How does DaVita compare to Cardinal Health?

Does the media favor DVA or CAH?

Which has preferable valuation and earnings, DVA or CAH?

Do insiders and institutionals believe in DVA or CAH?

Do analysts rate DVA or CAH?

Which has more risk & volatility, DVA or CAH?

Is DVA or CAH more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DVA vs. The Competition

DaVita Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools